Article
Improving patient outcomes to targeted therapies in melanoma.
Expert review of anticancer therapy - 1 Jun 2016
Eroglu Zeynep, Smalley Keiran S M, Sondak Vernon K
Abstract excerpt
INTRODUCTION: The arrival of targeted therapies has led to significant improvements in clinical outcomes for patients with BRAFV600 mutated advanced melanoma over the past five years. AREAS COVERED: In several clinical trials, BRAF and MEK inhibitors have shown improvement in progression free and overall survival, along with much higher tumor response rates in comparison to chemotherapy, with the combination of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.